Abstract:Background: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. The majority of patients can be cured under the treatment of R-CHOP, but one third of patients will relapse and have a worse prognosis. To exploring a biomarker which can predict clinical behavior may aid in the implementation of novel therapeutic strategies. Inhibitor of DNA-binding 3 (ID3) is a helix loop-helix transcription factor, which negatively regulates the cell proliferation. ID3 mutations occur in 34-68% of Bukitt's lymphoma (BL) and are assiociated with lymphomagenesis. A variety of nonsense and frameshift mutations in ID3 as well as missense mutations in the region encoding the HLH domain reduces or eliminates ID3 protein function in BL. ID3 mutation is rare in DLBCL. The prognostic value of ID3 protein level remains unclear in DLBCL. Therefore, we conducted a retrospective study to investigate the impact of ID3 expression in DLBCL patients. Methods: One hundred DLBCL patients treated at Fudan University Shanghai Cancer Center with available diagnostic biopsy material were identified. ID3 expression was determined and quantified by immunohistochemistry (IHC) with staining intensity and percentage of positive cells (IRS). The IRS cut off value for ID3 positive is equal or more than 6. Kaplan-Meier and life table method were used to calculate progression free survival (PFS) and overall survival (OS). Curves were compared with the long-rank test in both groups. Correlation between the ID3 expression and clinical variables were tested by Pearson Chi Square test and a two-sided P value of <0.05 was considered to be statistically significant. Result: Seventy-seven (77%) of patients was overexpressed ID3 and 23% patients was shown ID3 negative. Among these pateints, ID3 positive patients had a trend of better outcome without a significance. The PFS and OS were 65% and 68% in ID3 negative group; 80% and 85% in ID3 positive group, respectively. According to cell of origin, the ID3 deficiency were 24% (10/41) in GCB patients and 22% (13/59) in non-GCB patients (p=0.82). the ID3 overexpression was associated with a better OS compared with ID3 negative patients in non-germinal center B-cell lymphoma group (non-GCB) (85% vs 46%, p=0.047). Although the PFS of ID3 positive patients was better than negative group (77% vs 59%, p=0.256), there was no significance. In GCB patients, there was no differences between the ID3 positive group and negative groups in terms of PFS or OS. The basic characteristics were no difference between ID3 positive and negative groups. Conclusion: This is the first report demonstrating that ID3 overexpression is a positive predictor of clinical outcome in non-GCB lymphoma patients. ID3 is a potential novel target to treat lymphoma and further investigation of ID3 need to be done in the near future. (Research supported by National Natural Science Foundation of China (no.81670177, no.81001048) Figure Disclosures No relevant conflicts of interest to declare.

Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma

Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma

Data from Clinical Implications of Phosphorylated STAT3 Expression in <i>de Novo</i> Diffuse Large B-cell Lymphoma

Clinical significance and prognostic value of STAT 3 expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy

Enhanced IFN Sensing by Aggressive Chronic Lymphocytic Leukemia Cells

MYC/BCL2 Protein Co-Expression Defines a Unique Subset of Aggressive Lymphoma and Contributes to the Inferior Prognosis of Activated B-cell Subtype of Diffuse Large B-cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program Study

Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression

B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors

B-cell Receptor-Mediated NFATc1 Activation Induces IL-10/STAT3/PD-L1 Signaling in Diffuse Large B-cell Lymphoma

Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion

Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma

A novel function of STAT3β in suppressing interferon response improves outcome in acute myeloid leukemia

STAT3, tumor microenvironment, and microvessel density in diffuse large B cell lymphomas

High Nuclear Expression of STAT3 is Associated with Unfavorable Prognosis in Diffuse Large B-cell Lymphoma

Inhibitor of DNA Binding 3 Is a Potential Prognostic Biomarker in Non-GCB Diffuse Large B-Cell Lymphoma

STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma.

STAT3-coordinated migration facilitates the dissemination of diffuse large B-cell lymphomas

BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFNγ-STAT1-IRF1-p53 axis in diffuse large B-cell lymphoma

The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma

STAT6 mutations enriched at diffuse large B-cell lymphoma relapse reshape the tumor microenvironment

Susceptibility of pediatric acute lymphoblastic leukemia to STAT3 inhibition depends on p53 induction